Pregnancy in Women with Atypical Hemolytic Uremic Syndrome.
Atypical hemolytic uremic syndrome
Eculizumab
Pregnancy
Real-world evidence
Registry
Journal
Nephron
ISSN: 2235-3186
Titre abrégé: Nephron
Pays: Switzerland
ID NLM: 0331777
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
12
2020
accepted:
24
06
2021
pubmed:
14
9
2021
medline:
22
3
2022
entrez:
13
9
2021
Statut:
ppublish
Résumé
Pregnancy outcomes in patients with atypical hemolytic uremic syndrome (aHUS) are not well-documented. Here, we present characteristics of and outcomes for patients with aHUS who became pregnant while enrolled in the Global aHUS Registry. The observational Global aHUS Registry (NCT01522183), initiated in April 2012, collects demographics, disease history, treatment, and outcomes data for patients with aHUS, regardless of treatment approach. This descriptive analysis includes patients from the Registry with evaluable pregnancy data supplemented with pharmacovigilance information; the number of pregnancies, outcomes, and exposure to eculizumab were evaluated. As of April 1, 2019, 44 pregnancies were recorded in 41 patients, with 24 pregnancies exposed to eculizumab. Pathogenic variants were identified in 48.8% of patients. Three patients were on dialysis and 6 patients had a kidney graft at the time of pregnancy. Excluding elective terminations, 85.3% of pregnancies resulted in live births. Elective terminations were recorded in 22.7% of pregnancies, miscarriages occurred in 9.1% of pregnancies, and late fetal death in 2.3% of pregnancies. No malformations or anomalies were reported. Our results show that in women with aHUS, even on dialysis or with a kidney graft, pregnancy is possible with careful monitoring for aHUS flares and prematurity. Prophylactic or therapeutic eculizumab offers disease control with low-risk of fetal abnormalities.
Sections du résumé
BACKGROUND
Pregnancy outcomes in patients with atypical hemolytic uremic syndrome (aHUS) are not well-documented. Here, we present characteristics of and outcomes for patients with aHUS who became pregnant while enrolled in the Global aHUS Registry.
METHODS
The observational Global aHUS Registry (NCT01522183), initiated in April 2012, collects demographics, disease history, treatment, and outcomes data for patients with aHUS, regardless of treatment approach. This descriptive analysis includes patients from the Registry with evaluable pregnancy data supplemented with pharmacovigilance information; the number of pregnancies, outcomes, and exposure to eculizumab were evaluated.
RESULTS
As of April 1, 2019, 44 pregnancies were recorded in 41 patients, with 24 pregnancies exposed to eculizumab. Pathogenic variants were identified in 48.8% of patients. Three patients were on dialysis and 6 patients had a kidney graft at the time of pregnancy. Excluding elective terminations, 85.3% of pregnancies resulted in live births. Elective terminations were recorded in 22.7% of pregnancies, miscarriages occurred in 9.1% of pregnancies, and late fetal death in 2.3% of pregnancies. No malformations or anomalies were reported.
CONCLUSIONS
Our results show that in women with aHUS, even on dialysis or with a kidney graft, pregnancy is possible with careful monitoring for aHUS flares and prematurity. Prophylactic or therapeutic eculizumab offers disease control with low-risk of fetal abnormalities.
Identifiants
pubmed: 34515154
pii: 000518171
doi: 10.1159/000518171
pmc: PMC8820436
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-10Informations de copyright
The Author(s). Published by S. Karger AG, Basel.
Références
Nephrol Dial Transplant. 2016 Dec;31(12):2122-2130
pubmed: 27587606
Clin J Am Soc Nephrol. 2013 Apr;8(4):554-62
pubmed: 23307876
Kidney Int Rep. 2019 Jan 15;4(5):733-739
pubmed: 31080930
Lancet. 2017 Aug 12;390(10095):681-696
pubmed: 28242109
Lancet Glob Health. 2019 Jan;7(1):e37-e46
pubmed: 30389451
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1964-78
pubmed: 26487769
BMJ. 1997 Jul 5;315(7099):32-4
pubmed: 9233324
Nephrol Dial Transplant. 2015 Apr;30(4):652-61
pubmed: 25523452
J Am Soc Nephrol. 2018 Mar;29(3):1020-1029
pubmed: 29282226
BMC Nephrol. 2015 Dec 10;16:207
pubmed: 26654630
J Nephrol. 2016 Jun;29(3):277-303
pubmed: 26988973
Exp Hematol Oncol. 2017 Jan 13;6:4
pubmed: 28101432
Obstet Gynecol. 2020 Jan;135(1):46-58
pubmed: 31809447
Br J Haematol. 2019 Apr;185(2):297-310
pubmed: 30768680
Obstet Gynecol. 2013 Aug;122(2 Pt 2):487-489
pubmed: 23884270
Nefrologia. 2015;35(5):421-47
pubmed: 26456110
Lancet. 2016 Jul 16;388(10041):258-67
pubmed: 27179755
Natl Vital Stat Rep. 2012 Jun 20;60(7):1-21
pubmed: 22970648
Kidney Int. 2017 May;91(5):1047-1056
pubmed: 28209334